中科藍訊(688332.SH):募投項目—發展與科技儲備基金中,包含智能可穿戴眼鏡芯片研發
格隆匯8月16日丨中科藍訊(688332.SH)在投資者互動平台表示,目前,公司藍牙音頻芯片AB5656C2、AB5636A已分別應用於MINISO名創優品智能音樂眼鏡、WITGOER智國者S03智能音頻眼鏡,具有支持清晰語音通話、音樂播放、智能拍照等功能。公司募投項目—發展與科技儲備基金中,包含智能可穿戴眼鏡芯片研發,後續,公司將結合業務實際需求和發展戰略規劃,將募集資金投入到日常經營中,進一步鞏固並提升產品的市場競爭力,完善公司在智能穿戴的產品佈局,提高核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.